BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Melbourn Scientific to Announce First Comprehensive Nasal Device Testing Lab at ICSE


9/18/2012 10:34:43 AM

September 18, 2012 -- The multiple benefits of a nasal spray has triggered a boom in product development activity generating greater demand for Melbourn Scientific’s expertise in formulation analysis and performance testing. In response the company has created a dedicated laboratory to provide GMP testing of nasal device performance, the first in Europe to offer such a comprehensive service.

Mark Hammond, CEO of Melbourn Scientific says:

“We predicted a few years ago that nasal delivery of compounds would increase as companies realised the benefits of this route. A nasal device offers a user friendly, painless, non-invasive route for drug administration.

“We are now seeing evidence of continued growth and that clients recognise the advantages of working with partners that have expertise in this area of drug delivery and understand the formulation and analytical challenges that it brings.

The portfolio of nasal spray services offered by Melbourn includes: nasal device performance testing, droplet size and distribution analysis, spray pattern and plume geometry analysis. The new laboratory was included within a recent FDA inspection, which the company passed with ‘no significant deficiencies noted and no 483s issued’.

“The high surface area in the nasal cavity provides drugs with direct access to the systemic circulation providing rapid onset of action. This route also avoids any degradation from first pass metabolism, which means lower doses can be given reducing the possibility of unwanted side effects.”

The nasal cavity has a large surface area and high permeability, and the location of lymphoid tissue at the back of the nasal cavity offers rapid transport into the systemic circulation. The olfactory region at the top of the nasal cavity is of interest for the treatment for age-associated diseases such as Alzheimer’s, as it allows rapid absorption into the central nervous system.

The nasal route can also enhance performance for a wide range of treatments from the instant relief of panic attacks through to needle-free vaccinations.

However, the challenge of a nasal delivery device is to get the particle size right in order to ensure that the drug is deposited within the nasal passages and not the lungs or gastro-intestinal tract. This is where a comprehensive testing regime is beneficial.

Mark explains, “Depending upon the drug and device properties there are a number of considerations for the formulation, here at Melbourn Scientific we have developed a range of screening tools to enable us to fast track formulation development of the product from simple solutions, through suspensions to dry powder blends using a wide range of excipients.

“Our formulation development is supported by standalone testing services with significant investment in specialist equipment. The new lab will make this available as a comprehensive service. “

Equipment includes: the Malvern Spraytec, which is designed to capture information about both pulsed spray and continuous spray events, Morphologi G3 an optical imaging tool that provides more information about individual particles giving data about their size, shape and solidity and the new Proveris’s SprayVIEW, a FDA accepted spray pattern and plume geometry analysis service.

Melbourn Scientific has also appointed a new business development executive Liz Parkhouse to provide a point of contact for the nasal spray testing service. She will be at ICSE to talk to visitors.

See us on ICSE stand no. 8J24, 9-11th October 2012, Madrid. www.icsexpo.com

Please contact Rachel Holdsworth/Nina Beadle/Claire Lynn, 01954 202789, nina@holdsworth-associates.co.uk, www.holdsworth-associates.co.uk

Melbourn Scientific:

Mark Hammond, CEO, Melbourn Scientific Ltd, 01763 261648, www.melbournscientific.com

About Melbourn Scientific www.melbournscientific.com

Melbourn Scientific, based near Cambridge UK, provides high quality analytical and formulation services to the pharmaceutical and healthcare industry. Clients include major pharmaceutical companies, drug delivery innovators, consultants and virtual companies.

Melbourn Scientific has invested continually in the latest equipment and provides a range of services; formulation and product development; method development and analytical support; stability studies and storage; accelerated feasibility studies, GMP facilities and manufacturing.



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES